PUCAI calculator
Use six weighted items to score pediatric UC activity (0-85), then apply severity-based escalation and trend reassessment.
Last reviewed: February 25, 2026
Clinical disclaimer
How PUCAI works
Six weighted items are summed: abdominal pain (0/5/10), rectal bleeding (0/10/20/30), stool consistency (0/5/10), number of stools (0/5/10/15), nocturnal stools (0/10), and activity level (0/5/10). Bands: remission <10; mild 10–34; moderate 35–64; severe ≥65. Do not impute missing items.
Score only with complete same-day clinical data; mixing historical and current symptoms can overstate or understate flare severity.
Interpretation and trending
- Use trends over time; compare against baseline and treatment milestones (induction, maintenance).
- Remission <10 often correlates with improved quality of life; confirm with labs/stool markers and growth.
- Rising scores should prompt adherence checks, infection screening (e.g., C. difficile), and review of recent medication changes.
Escalation and hospitalization
- Severe PUCAI (≥65), significant weight loss or dehydration, concern for toxic megacolon, or severe bleeding warrants hospital care and IV steroids per pathway.
- For moderate scores, consider step-up therapy, steroid-sparing approaches, and closer follow-up. Engage GI early when scores climb despite outpatient management.
- Monitor for complications: anemia, electrolyte derangements, and thromboembolic risk in severe flares.
Rapid flare workflow (first 24 hours)
- Calculate PUCAI with full symptom set and confirm no missing items.
- For moderate-to-severe scores, screen immediately for dehydration, anemia, infection, and toxic-colitis warning signs.
- Trigger local UC flare pathway actions, including stool testing and supportive care.
- Set explicit reassessment interval (often 24-48 hours in active flares).
- Escalate early to inpatient or tertiary IBD support if trajectory worsens.
Monitoring and supportive care
- Pair PUCAI with CRP/ESR, albumin, and stool calprotectin as available; track trends rather than single data points.
- Track growth and nutrition; involve dietitians for calorie, protein, and micronutrient optimization.
- Assess for extraintestinal manifestations (joints, skin, eyes, hepatobiliary) and manage or refer as indicated.
- Review immunizations and infection prophylaxis when on steroids/biologics.
Documentation checklist
- PUCAI item scores with stool counts and bleeding details.
- Weight, growth trends, and hydration status.
- Lab and stool marker trends plus infection screening.
- Treatment plan, response timeline, and follow-up interval.
Common failure modes
- Escalating immunosuppression before excluding infectious flare mimics.
- Using single PUCAI values without trend context across treatment milestones.
- Underweighting hydration and nutrition decline when score changes appear modest.
- Missing nocturnal stool detail, leading to underestimated severity.
Immediate escalation triggers
- Severe score band with systemic instability, dehydration, or significant bleeding.
- Rising score despite initial treatment and supportive measures.
- Concern for toxic megacolon, severe anemia, or rapid nutritional decline.
- Infection uncertainty (e.g., C. difficile) complicating immunosuppression decisions.
Handoff template
- Current PUCAI total plus individual item drivers (bleeding, stool frequency, nocturnal stools).
- Hydration/nutrition status and recent weight trend.
- Current lab/stool marker results and infection workup status.
- Therapeutic changes made and expected response interval.
- Escalation trigger and next reassessment timing.
Treatment considerations (contextual)
Use PUCAI to frame disease activity; therapeutic decisions should follow your IBD protocol. Consider steroid tapers, 5-ASA optimization, immunomodulators, or biologics based on severity, prior response, and risk profile. Educate families on adherence, infection precautions, and when to call.
Related tools
- sPCDAI for Crohn’s disease activity.
- Pediatric Vital Signs to interpret vitals during flares.
- Pediatric eGFR when dosing renally cleared meds or monitoring renal function.
References
FAQs
Common bands: remission <10; mild 10–34; moderate 35–64; severe ≥65. Always interpret with clinical context, growth, and labs/stool markers.
No. Complete the clinical assessment before scoring; missing data can distort severity categorization.
Severe PUCAI (≥65), significant weight loss, dehydration, concern for toxic megacolon, severe bleeding, or failure of outpatient management warrant hospital-level care and IV steroids per pathway.
Trend at every clinical touchpoint during flares or induction, and periodically in maintenance. Use trends with labs/stool markers to guide therapy adjustments.
No. Use the sPCDAI or other Crohn’s-specific indices for Crohn’s disease activity.
Many protocols consider a 20-point decrease meaningful response, but thresholds vary. Compare with symptoms, labs, and growth.
Yes. Intercurrent infections, especially C. difficile, can increase stool frequency and bleeding scores. Reassess with stool testing and clinical context before escalating long-term UC therapy.
Not always. Small short-term changes can be misleading; persistent moderate/severe burden or clinical decline should still trigger timely escalation.